menu search

Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®

Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®
Prolaris is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, Aug. 15, 2023 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN) a leader in genetic testing and precision medicine, today announced the integration of Absolute Risk Reduction (ARR) into the Prolaris® Prostate Cancer Prognostic […] The post Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris® appeared first... Read More
Posted: Aug 15 2023, 11:05
Author Name: forextv
Views: 092035

Search within

Pages Search Results: